Cargando…

Off-label use of orphan medicinal products: a Belgian qualitative study

BACKGROUND: Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan medicinal produ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dooms, Marc, Cassiman, David, Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086036/ https://www.ncbi.nlm.nih.gov/pubmed/27793155 http://dx.doi.org/10.1186/s13023-016-0507-y

Ejemplares similares

Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
por: Picavet, Eline, et al.
Publicado: (2013)

Clinical evidence for orphan medicinal products-a cause for concern?
por: Picavet, Eline, et al.
Publicado: (2013)

Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014)

Shining a light in the black box of orphan drug pricing
por: Picavet, Eline, et al.
Publicado: (2014)

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice
por: Janssens, Rosanne, et al.
Publicado: (2018)

Understanding off-label use and the new challenges
por: Dooms, Marc
Publicado: (2014)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
por: Dooms, Marc M
Publicado: (2016)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021)

Rare diseases and orphan drugs: 500 years ago
por: Dooms, Marc M.
Publicado: (2015)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Orphan medical devices have come a long way
por: Dooms, M.
Publicado: (2023)

Market access of orphan drugs and the role of multi-criteria decision making
por: Simoens, Steven
Publicado: (2012)

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
por: Pauwels, Kim, et al.
Publicado: (2017)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
por: Morel, Thomas, et al.
Publicado: (2013)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Challenges on off label medicine use
por: Carvalho, Marisa Lima
Publicado: (2016)

A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
por: Abdallah, Khadidja, et al.
Publicado: (2021)

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
por: Stolk, Pieter, et al.
Publicado: (2009)

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

Financial based agreements and performance based agreements: the Belgian experience
por: Pauwels, Kim, et al.
Publicado: (2015)

Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
por: Morel, T., et al.
Publicado: (2016)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

By Belgians for Belgians
por: Childers, M. A.
Publicado: (1915)

Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
por: Pijeira Perez, Yankier, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1rc4mgplrc8usnst7brnntskcl